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Abstract
Background: Evidence demonstrates that measures are needed to optimise therapy and improve administration of
medicines in care homes for older people. The aim of this study is to determine the clinical and cost effectiveness
of a novel model of multi-professional medication review.
Methods: A cluster randomised controlled trial design, involving thirty care homes. In line with current practice
in medication reviews, recruitment and consent will be sought from general practitioners and care homes,
rather than individual residents. Care homes will be segmented according to size and resident mix and
allocated to the intervention arm (15 homes) or control arm (15 homes) sequentially using minimisation.
Intervention homes will receive a multi-professional medication review at baseline and at 6 months, with follow-
up at 12 months. Control homes will receive usual care (support they currently receive from the National Health
Service), with data collection at baseline and 12 months. The novelty of the intervention is a review of
medications by a multi-disciplinary team. Primary outcome measures are number of falls and potentially
inappropriate prescribing. Secondary outcome measures include medication costs, health care resource use,
hospitalisations and mortality.
The null hypothesis proposes no difference in primary outcomes between intervention and control patients. The
primary outcome variable (number of falls) will be analysed using a linear mixed model, with the intervention
specified as a fixed effect and care homes included as a random effect. Analyses will be at the level of the care
home. The economic evaluation will estimate the cost-effectiveness of the intervention compared to usual care
from a National Health Service and personal social services perspective.
The study is not measuring the impact of the intervention on professional working relationships, the medicines
culture in care homes or the generic health-related quality of life of residents.
Discussion: This study will establish the effectiveness of a new model of multi-professional clinical medication
reviews in care homes, using novel approaches to recruitment and consent. It is the first study to undertake an
examination of direct patient outcomes, together with an economic analysis.
Trial Registration: ISRCTN: ISRCTN90761620
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This trial is concerned with the management of medi-
cines in care homes. In 2001 there were 528,000 regis-
tered beds in 27,480 general residential and nursing
homes in the UK and by 2020 this is predicted to
increase by 23% [1]. General Practitioners (GPs) have
principal responsibility for the medical care of care
home residents and, owing to the relatively high mor-
bidity in this population, the size of the care home
population has a major impact on their overall workload
[2]. Care home residents are commonly the most infirm
members of the primary care community with 82% of
older people in care homes having long-standing illness
and 48% having two or more chronic conditions [3].
The high level of morbidity in this population is asso-
ciated with a high level of prescription medicines, with
care home (residential and nursing) residents receiving
an average of seven medicines [4,5]. A report by the
National Care Standards Commission (NCSC) in 2004
suggested that care providers seek greater involvement
of pharmacists in medicines management issues and
that primary care should consider commissioning
reviews of prescribing practice in care homes after they
found that only 44% of care homes for older people met
the national minimum standards on medication [3].
Evidence demonstrates that medicines management of
residents in care homes for older people could be signif-
icantly improved [6]. Medication reviews for such
patients have identified high proportions of patients
receiving sub-optimal therapy, with the main medication
error being the continuation of medication that is no
longer required [7,8]. Other problems have been identi-
fied, such as prescribing medication to counteract side
effects of other medication [9], or prescribing without
monitoring [10] - the exact extent of these problems is
unknown. Poor medicines management leads to thera-
peutic failure and influences the likelihood of adverse
events, for example, increasing number of falls [11] or,
in the case of certain drugs used in patients with
dementia, reducing survival [12]. There have been a
number of calls for measures to optimise therapy and to
improve the administration of medicines in this context
[13], with a multi-disciplinary approach to care recom-
mended [14].
Although studies of pharmacist medication reviews in
primary care have demonstrated pharmacists’ ability to
identify and resolve drug-related problems and reduce
prescribing [15-17], these results have not been generali-
s a b l ea st h e yt e n d e dt ou s eas m a l ln u m b e ro fp h a r m a -
cists. Studies that have used a larger number of
pharmacists are usually confounded by lower quality
relationships with prescribers and have failed to identify
significant improvements in clinical outcomes [18-22],
with one study identifying an increase in hospital admis-
sions [23].
Pharmacist-led medication reviews in care homes have
also demonstrated the ability to reduce the number of
prescribed medicines, but failed to detect significant
change in morbidity or mortality [7,24]. Zermansky et
al. performed a Randomised Controlled Trial (RCT) on
661 care home residents [5]. One clinical pharmacist
performed the medication reviews and made recommen-
dations to the GP. After six months follow-up the num-
ber of medication changes in the intervention group had
significantly increased and the number of falls was
reduced, but no other patient benefits were detected.
Very few RCTs of pharmacist-led medication reviews
in the UK have included an economic evaluation. The
aim of most pharmacist medication review studies has
been to improve patient treatment by altering medica-
tion, thus medication costs have been included in three
RCTs which demonstrated favourable prescribing out-
comes [5,15,17]. Furniss et al’s. RCT in nursing homes
considered the costs (using local figures) of all primary
and secondary care contact for each resident. However,
the authors reported that formal economic evaluation
was not possible as healthcare professionals often visited
patients not included in the study during their visits [7].
It is evident from the research available that pharma-
cists working in isolation have limited impact on patient
orientated outcomes in care homes and have failed to
demonstrate cost effectiveness. The aim of this RCT is
to determine the clinical and cost effectiveness of a
multi-professional team approach to medication reviews
in care homes.
This novel model of medication review was developed
by a Primary Care Trust (PCT) Medicines Management
Team (MMT) in collaboration with GPs and after con-
sultation with geriatricians. Within the NHS, PCTs are
responsible for the care of approximately 500,000
patients within a local area, assessing need and commis-
sioning care. The vast majority of care is commissioned
from independent providers such as GP practices, Com-
munity Pharmacists, Dentists and other healthcare pro-
viders. All PCTs include a MMT who are responsible
for managing prescribing budgets and prescribing sys-
tems, together with supporting primary care providers.
Therefore, many PCTs employ pharmacists and techni-
cians to work with GP practices to support prescribing
and this often involves reviewing patients’ medication.
This activity is usually completed independently by the
MMT and then interventions are agreed with the pre-
scriber at a later date. By improving the management of
medicines, the new model under evaluation is designed
to deliver better health outcomes for care home resi-
dents and enhance the use of healthcare resources. The
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approach, involving pharmacists, pharmacy technicians
and care home staff, as well as the GP(s) responsible for
the medical care of residents. The multi-disciplinary
team meet together to review and discuss the medica-
tions of care home residents. This model has the poten-
tial for wider implementation, but the effectiveness of
this approach requires evaluation.
The clinical medication review involves consideration
of patients’ medical history, recent blood test results and
current medications. Prior to the meeting the pharma-
cist will review patient data and prepare a list of recom-
mended actions. The latter will be considered at the
review meeting, with the pharmacist drawing on the
expertise of the GP and care home staff. The medication
review is designed to identify the high instances of inap-
propriate prescribing in care home residents[25], reduce
the number of medication errors [4] and increase the
frequency of monitoring. The majority of drug-related
problems in care home residents relate to psychoactive
medication [26] and therefore stopping these medica-
tions, combined with the other benefits of a clinical
medication review in this population, is predicted to
reduce falls [27]. The review meeting also offers the
opportunity for generic medicines management issues at
the home to be raised.
The objectives of the RCT are to determine the
impact of the multi-professional medication review ser-
vice (MMRS) on the number of falls and potentially
inappropriate prescribing (number of drugs which
match the Screening Tool of Older Persons Prescrip-
tions (STOPP) criteria [28] at each data collection
point). The trial will also examine the impact on medi-
cation costs, utilisation of health and social care
resources, and mortality. The primary analysis is a direct
comparison of the two groups: intervention and control.
Analyses will essentially be at the level of the care home
rather than the patient (see section entitled Clinical
analysis).
Methods
Trial design
A cluster randomised controlled trial will be used and a
flow chart outlining the study design appears in Figure
1. The project will involve care homes for older people
(average age > 65 years) registered with a GP in the
local area. Thirty care homes will be recruited to the
trial: 15 in the intervention arm and 15 in the control
arm. Intervention homes will receive a MMRS at base-
line and six months, with final data collection at 12
months. Control homes will receive usual care (support
they currently receive from the National Health Service
(NHS)) with data collection at baseline and at 12
months. Following final data collection at the control
homes, a MMRS can be implemented.
The study has ethical approval from the NHS Norfolk
Research Ethics Committee (REC reference 09/H0310/
96).
Recruitment
In the first instance, the GP practices responsible for the
medical care of residents will be contacted by letter and
accompanying information sheet to advise them of the
study. It is expected that support and endorsement of
the study by the Chairs of the Locality Prescribing
Groups and the Primary Care Research Network will
assist in promoting the study. A follow-up phone call
from a researcher will establish expressions of interest
and arrange a face-to-face meeting to explain the study
in more detail.
Following agreement from GPs to include the MMT
in the service responsible for the clinical care of care
home residents, care homes will be approached for their
consent. It is expected that care homes will be more
willing to consider participation if they know that the
GP practices have already given their consent to taking
part in the study. A similar process of contact will be
used, i.e. initial contact by letter and information sheet,
with follow-up phone call and face-to-face meeting.
Consent will be sought at the care home management
level, rather than individual resident level. The process
of obtaining consent from GPs and care home managers
is in line with current practice for medication reviews in
care homes.
The intervention is at the level of the home and, fol-
lowing standard practice, all residents in the home will
have their medication reviewed. A leaflet will be given
to residents (or their relatives) informing them about
the study.
Eligibility of care homes
There are more than 130 care homes in the PCT area,
but after all exclusions it is predicted there will be
approximately 65 care homes eligible for participation.
In order to take part the care homes must be for older
people (average age >65 years) and have been registered
with the Care Quality Commission (CQC) for at least
six months. Care homes specifically for people (of all
ages) with learning disability, sensory impairment, men-
tal health problems, physical disabilities and alcohol
dependence will be excluded. Care homes will also be
excluded if they have received a medication review ser-
vice from the PCT in the last 6 months, if they receive
the services of a community geriatrician or if they are
subject to investigation of the safeguarding of vulnerable
adults.
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residents who self-medicate will be excluded. Those
residents who are in the home for respite care will also
be excluded.
Allocation to treatment
Care homes will be segmented according to their resi-
dent mix (three categories: care home, care home with
nursing, care home with residential and nursing beds)
2-weeks 
2-weeks 
Initial contact with practice 
managers and GPs for consent 
Care homes invited to participate 
 
GP/Care homes 
decline 
Recruited care homes 
randomised 
1) Pharmacy technician 
confirms list of patients and 
collects baseline data 
2) Pharmacist 
prepares care plan 
Pharmacy technician confirms 
list of patients and collects 
baseline data 
INTERVENTION  CONTROL 
3) Multi-professional 
medication review 
meeting, action plan 
agreed 
4) Action plan implemented and records 
updated.  Written details of all changes 
communicated with care home and 
community pharmacist 
Stages 1-4 are repeated and 6-
Month data collection 
12-Month data collection  12-Month data collection 
Care home can receive 
intervention 
6 Months 
12 Months 
12 Months 
Analysis 
Dissemination 
Figure 1 Flow chart of trial design.
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small, medium and large). Recruitment will then pro-
ceed in ‘waves’.
In the first wave a relatively homogeneous block of
homes with approximately 30 residents will be
approached as this represents the optimum number of
residents for delivery of the intervention. For the second
and subsequent waves, the homes to be approached will
be decided purely on the basis of facilitating recruit-
ment. For practical (i.e. workload) reasons, consenting
homes will be allocated to intervention or control
sequentially after consent is obtained using minimisa-
tion. This strategy has the advantage of achieving
approximate balance between treatment groups with
respect to stratifying factors (here resident mix and size)
whilst allowing the practical advantage of being able to
make allocations sequentially as homes are recruited,
rather than having to wait for blocks to accumulate.
Recruitment will cease once approximately 900 residents
have been recruited.
Sample size estimation
Previous research suggests that medication review ser-
vices can reduce the average number of falls per patient
over a 6 month period by 0.59 (confidence interval: 0.49
to 0.70), with a variance per patient of four [5]. This
study was conducted in a similar setting and therefore
we estimate the baseline frequency of falls to be similar
(approximately 1 per resident per six months). Using
the lower end of this confidence interval, 261 patients in
each group would be required to detect this difference
with 80% power and at the 5% level of significance.
Assuming the intra-cluster correlation coefficient is 0.02
then in an average home (30 residents) this sample size
needs to be multiplied by 1.58 [29] (the design effect
allowing for clustering). Thus a total of 824 patients
(412 in each group) will need to be recruited from
approximately thirty homes. In recruiting 30 homes
with an average of 30 residents this will allow for 10%
losses to follow-up.
Intervention
This is the first study that brings together a multi-disci-
plinary team to review the medications of care home
residents in a face-to-face meeting where they are able
to draw on, and benefit from, one another’se x p e r t i s e .
The intervention is a multi-professional medication
review meeting involving a clinical pharmacist and phar-
macy technician from the PCT MMT, care home staff
and GP(s) responsible for the medical care of residents.
All pharmacists (n = 4 to 8) and technicians (n = 4 to
8) participating in this study have previous experience
of reviewing the medication of care home residents. It is
hypothesised that this model of medication review
service has greater potential to deliver benefits to
patients than a pharmacist working in isolation on a
medication review (i.e. examining patients’ clinical
records and making recommendations to the GP at a
later date in writing or face-to-face).
The first medication review meetings will take place at
the care homes approximately four weeks after alloca-
tion to treatment and a second medication review will
take place at the 6 month point after allocation to treat-
ment. Each medication review meeting will (on average)
consider 15 residents and is expected to last for up to
two hours. Thus two face-to-face meetings will be
necessary for a care home with around 30 residents and
more than two will be required for larger care homes.
The medication review meeting is organised by the
pharmacy technician from MMT. The technician will
liaise with the care home, GP(s) and the clinical phar-
macist (MMT) in order to agree a date and time for the
meeting(s). As part of the process of consent, GP prac-
tices and care homes have agreed to commit staff time
to the medication review meetings. The technician is
also responsible for the necessary data extraction from
GP practices prior to the medication review meeting.
This involves generating patient summary data (see
below) - information that allows the clinical pharmacist
to complete their preparation for the review meeting.
About one month prior to the intervention (or medi-
cation review meeting), a PCT MMT pharmacy techni-
cian will visit the care home and obtain a list of
residents and their associated GP practices, plus ensure
relevant blood tests have been requested with district
nurses. Two weeks prior to the planned review meeting
the technician will obtain a computer-generated patient
summary from the GP practices for each resident to be
reviewed. This will include details of current medication,
past medical history and recent blood tests. The patient
summary data is passed to the clinical pharmacist from
MMT. As part of their preparation for the medication
review meeting, the clinical pharmacist will prepare a
pharmaceutical care plan for each care home resident
considering a number of factors, including: the indica-
tion, need, evidence base and PCT guidelines for each
medication and medical problem. The care plan will
also consider any interactions, unmet pharmaceutical
needs and clinical appropriateness of each medication.
During the review meeting, each resident’sc a r ep l a n
and the associated list of recommended actions prepared
by the clinical pharmacist will be discussed by the multi-
disciplinary team. As the meeting takes place at the care
home, the Medicines Administration Record (MAR)
Charts can be consulted during the course of the discus-
sion and any discrepancies with the resident care plan
will be identified. A joint decision on action plans will
be agreed by the clinical pharmacist, GP, care home
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The medication review meeting also provides care home
staff with the opportunity to discuss with the clinical
pharmacist any general issues relating to medicines
management at the care home.
After the review meeting, agreed action plans will be
implemented by MMT. The pharmacy technician will
update GP records and Read Code the medication
review. In addition, the technician will provide written
details of all agreed medication changes to the care
home and dispensing community pharmacist.
For those MMT members who are not as experienced
in care home medication reviews, training on study pro-
tocols will be provided by senior members of the MMT.
Where a clinical pharmacist undertakes a medication
review at a care home for the first time, a senior collea-
gue will evaluate the process and provide feedback. Peer
support from more experienced colleagues will be avail-
able to members of MMT throughout the study.
The medication review is not designed to focus speci-
fically on issues associated with falls, however many of
the interventions which are recommended by pharma-
cists in medication reviews are likely to impact this out-
come, as drug related falls are an important cause of
morbidity [30]. Examples include: stopping medication
which causes confusion (e.g. psychotropic medication)
or adjusting medication which improves mobility (e.g.
for Parkinson’s disease). It is recognised that the falls
prevention context is important and that any fall pre-
vention initiatives that are put in place during the study
period have the potential to influence the analysis.
While it is envisaged that any falls prevention initiatives
would be rolled out consistently across treatment and
control, members of the Management Group and Trial
Steering Committee (see section entitled Support for the
study) will advise the research team of any develop-
ments pertinent to the conduct of the study.
Data collection
Data will be collected from intervention and control
homes at three points (baseline, 6 months and 12
months) as follows. All patient demographic, medical
history, medication details and falls data (in previous six
months) will be obtained from records in the care home
(i.e. individual care plans and accident books) and GP
practices by a pharmacy technician one month prior to
the planned care home visit in intervention homes. For
the control homes, data collection at baseline will take
place as soon as possible after allocation (within a
month of allocation) and will be facilitated by the phar-
macy technician. The data collected at this point will
include patient demographic and falls data.
Details of all recommendations arising from the medi-
cation review, as well as implemented interventions, will
be recorded for intervention homes. This process will be
repeated after six months. After 12 months follow-up
this data will again be extracted from care home records
and GP practices (for intervention and control homes,
with data collection for the latter encompassing the 6
month and 12 month points) by a pharmacy technician.
Anonymised data will be passed to the research team
for analysis.
For the economic evaluation, data will be collected on
the time taken to develop and provide the intervention
and on the resource items likely to change as a result of
the intervention. Resource items will include visits to
(and from) health care professionals (such as GP, nurse
and dietician), as well as hospital and social services.
Outcome measures
The following primary outcome measures are being uti-
lised:
▪ Number of falls (mean per patient per month)
▪ Potentially inappropriate prescribing (number of
drugs which match the STOPP criteria [28] at each
data collection point).
Secondary outcome measures include:
▪ Medication costs (mean drug costs per patient -
net ingredient costs for 28 days)
▪ Utilisation of primary care, secondary care and
personal social services health professional time (GP,
nurse and other)
▪ Emergency hospital admissions and Accident and
Emergency (A&E) visits (number of admissions in
six months per patient)
▪ Mortality.
Support for the trial
In terms of infrastructure to support the trial and
ensure its completion, there are a number of mechan-
isms in place. In the first instance, the trial is supported
by input from a multi-disciplinary research team. In
addition to the Principal Investigator (PI), study coordi-
nator and senior pharmacists from the MMT, the team
is comprised of specialists in trial design, pharmacy
practice, statistics and health economics.
A Management Group will meet on a quarterly basis
throughout the duration of the trial. The Management
Group consists of the members of the research team, a
local GP representative, a community geriatrician, a falls
specialist, care home representative and two lay mem-
bers. The purpose of the Management Group is to set
objectives, agree timelines, monitor progress and facili-
tate study delivery and evaluation.
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vide overall supervision of the trial, with an emphasis on
trial progress, adherence to protocols, consideration of
new information pertinent to the trial, data monitoring,
reporting and ethical issues. The Steering Committee is
chaired by a statistician and has care home and PCT
expert representatives and two lay members. The PI and
study coordinator are also members of the Steering
Committee.
Clinical analysis
The null hypothesis is that there will be no difference in
primary outcomes between intervention and control
patients. All data will be stored on a relational database,
which will assist with ongoing management. Data will
then be arranged for further analysis in other programs
including Microsoft Excel
©, GenStat and SPSS
©.T h e
patient population will be characterised using the appro-
priate descriptive statistics, with medicines categorised
according to those described within the British National
Formulary (BNF) and medical problems classified
according to the World Health Organisation Interna-
tional Classification of Diseases (ICD-10). Descriptive
analysis of pharmaceutical care issues and action points
in intervention patients will be recorded.
In this paper we are restricting ourselves to a descrip-
tion of our primary analysis, which is a direct compari-
son of the two groups: intervention and control.
For the following outcome variables - number of falls,
emergency hospital admissions and deaths - the total
number of events in each care home will be aggregated,
along with total resident days ‘at risk’ i nt h es a m ep e r -
iod. The events data will be analysed by fitting a hier-
archical generalized linear mixed model to them. The
basic generalized linear model used will be a log-linear
model with Poisson error and log (’at risk’ days) as an
offset. The care homes themselves will be represented as
random effects. Fixed effects in the model will be the
intervention itself, the home size (small, medium, large),
and resident-type (a two-level factor: residential care vs
nursing care). The fact that ‘mixed’ homes have both
types of resident means that the event-counts and ‘at
risk’ days counts will have to be aggregated separately
for each type in these homes. The standard error asso-
ciated with the estimate of the effect of the intervention
will be adjusted as necessary to take account of the clus-
ter design. These models will be fitted in the GenStat
statistical package using residual maximum likelihood
(REML).
It is to be noted that the above analyses are essentially
at the level of the care home rather than the patient.
There are no identified covariates for the primary analy-
sis. However, exploratory analyses may be conducted at
the patient level, should a case emerge for including
patient-level covariates in a secondary analysis.
With respect to the study’s second primary outcome
variable measure (number of drugs which match the
STOPP criteria for each patient at each time point), this
will also be analysed using a generalized linear mixed
model. In this case there is a strong candidate for a
patient-level covariate, ie the number of drugs which
match the STOPP criteria at baseline. This variable will
be analysed at the patient-level, with the baseline covari-
ate (ie the number of drugs which match the STOPP
criteria at baseline). The basic generalized linear model
here will use a negative binomial distribution for the
error. The fixed and random effects will be as previously
stated.
Economic analysis
The economic evaluation will estimate the cost-effec-
tiveness of a MMRS in care homes for older people
compared to usual care from a NHS health and personal
social services perspective. Established and accepted eco-
nomic methodologies will be employed throughout
[31,32].
An incremental cost analysis will be undertaken.
Resource items likely to change as a result of the inter-
vention (as well as the cost of developing and providing
the intervention) will be identified, measured and
valued. Healthcare resource use data will be collected
from care home and GP records. The base case will cap-
ture only those costs incurred by the NHS (including,
for example, health care professionals’ time and travel to
medication reviews, patient visits with health care pro-
fessionals, admissions to secondary care, and medica-
tion) and personal social services. Unit costs will be
derived from national published data (for instance Cur-
tis 2009 [33]) for the most recent price year available.
This study will undertake a cost-effectiveness analysis
to address the technical efficiency question of how best
to provide medication review services to older people
living in care homes: by multi-professional teams or via
GP care (usual care). Effectiveness will be measured in
terms of the change in number of falls. If non-domi-
nance occurs (that is if costs are greater and the inter-
vention is more effective or if the intervention is
cheaper and less effective) an incremental cost-effective-
ness ratio (the ratio of additional cost divided by addi-
tional benefit) will be produced in terms of the
incremental cost per fall prevented. The confidence
region around the incremental cost effectiveness ratio
will be estimated using appropriate statistical techni-
ques. Since this economic evaluation is being underta-
ken alongside a cluster randomised trial the analysis
needs to reflect the increased uncertainty of
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of approaches have recently been proposed for this, with
each found to generate similar findings [34]. The sto-
chastic analysis will enable a cost effectiveness accept-
ability curve to be produced [35] illustrating the
decision uncertainty, that is the probability that the
MMRS in care homes for older people is cost-effective
compared to usual care for a range of willingness to pay
per fall prevented values. The timeframe for the eco-
nomic analysis will be that of the trial period.
Limitations
The MMRS has the potential to impact on a number of
factors that are not being measured in this study, but
are likely to be important for medicines management in
care homes. For example, the MMRS provides a positive
way for pharmacists to work with GPs and care home
staff. The review meeting offers an opportunity for the
professionals to build relationships and to achieve a
greater understanding of their respective roles and
responsibilities. The MMRS may also influence posi-
tively the medicines culture at the care home, by addres-
sing generic issues in the management and
administration of medicines. Further research could
explore such factors perhaps utilising action research or
other qualitative methodologies. The study is also not
measuring the impact of the intervention on the generic
health-related quality of life of residents.
Discussion
In January 2010 the Department of Health issued a CAS
Alert [31] calling for a safety review of all aspects of the
provision of medication to older people in care homes.
Alert (2010) 001 was issued following the publication of
the Care Homes Use of Medicines (CHUMS) [32] study
that identified a high prevalence of medication errors.
The alert calls for an integrated approach to determine
how medicines management in care homes might be
improved.
This study is seeking to establish the effectiveness of a
novel model of clinical medication review in care homes
involving a multi-professional approach. It is the first
study to undertake an examination of direct patient out-
comes together with an economic evaluation. The clini-
cal medication review is innovative in that it involves
the pharmacist working in collaboration with GPs and
care home staff.
The study also has novel approaches to recruitment
and consent. Care homes are being recruited with the
support and agreement of their GPs and consent for
participation in the study is being sought from GPs and
care home managers - and not individual residents. This
is because the intervention is provided at the level of
the care home (i.e. to all residents) as is standard
practice for the MMT team when delivering this service.
This approach has the advantage of simplifying the pro-
cess of securing informed consent. However, it does
mean that no additional information is obtained from
care home residents and, as indicated above under lim-
itations, the study does not measure the impact of the
intervention on, for example, residents’ health-related
quality of life.
The MMRS is intended to deliver improvements in a
number of areas, including the quality of prescribing,
increased patient monitoring, better health outcomes,
and a potential reduction in the number of medications
prescribed. Such a service will contribute to optimising
therapy, improving patient safety and minimising pro-
blems in the management of medicines at care homes.
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